贝达奎宁-话题@MedSci

#贝达奎宁#

5篇内容 | 762人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1412254, encodeId=2c601412254c9, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#贝达奎宁#</a>, objectTitle=含贝达奎宁的短期疗程方案治疗耐多药结核病的成本效益分析, objectType=article, longId=191963, objectId=c76e19196362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c76e19196362, replyNumber=0, likeNumber=38, createdTime=2020-04-12, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c76e19196362, moduleTitle=含贝达奎宁的短期疗程方案治疗耐多药结核病的成本效益分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c76e19196362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412253, encodeId=5b04141225316, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#贝达奎宁#</a>, objectTitle=贝达奎宁治疗耐多药和广泛耐药结核：安全有效, objectType=article, longId=191934, objectId=f08b19193483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f08b19193483, replyNumber=0, likeNumber=32, createdTime=2020-04-11, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f08b19193483, moduleTitle=贝达奎宁治疗耐多药和广泛耐药结核：安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f08b19193483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412252, encodeId=ec0d141225248, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#贝达奎宁#</a>, objectTitle=贝达奎宁治疗耐多药结核病的美国经验 , objectType=article, longId=191820, objectId=b450191820c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b450191820c1, replyNumber=0, likeNumber=32, createdTime=2020-04-10, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b450191820c1, moduleTitle=贝达奎宁治疗耐多药结核病的美国经验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b450191820c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412251, encodeId=154e1412251d3, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#贝达奎宁#</a>, objectTitle=EUR RESPIR J：贝达奎宁治疗耐多药结核的长期有效性和安全性, objectType=article, longId=191132, objectId=638519113241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=638519113241, replyNumber=0, likeNumber=49, createdTime=2020-04-01, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=638519113241, moduleTitle=EUR RESPIR J：贝达奎宁治疗耐多药结核的长期有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=638519113241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412250, encodeId=24f31412250fa, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#贝达奎宁#</a>, objectTitle=LANCET RESP MED：贝达奎宁显著降低耐药结核病患者的死亡率, objectType=article, longId=191131, objectId=01741911314e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01741911314e, replyNumber=0, likeNumber=55, createdTime=2020-04-01, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01741911314e, moduleTitle=LANCET RESP MED：贝达奎宁显著降低耐药结核病患者的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01741911314e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝达奎宁

2020-05-29

liuhuangbo (审核中...)

前往app查看评论内容

#贝达奎宁#

含贝达奎宁的短期疗程方案治疗耐多药结核病的成本效益分析

2020-04-12

liuhuangbo (审核中...)

前往app查看评论内容

#贝达奎宁#

贝达奎宁治疗耐多药和广泛耐药结核：安全有效

2020-04-11

liuhuangbo (审核中...)

前往app查看评论内容

#贝达奎宁#

贝达奎宁治疗耐多药结核病的美国经验

2020-04-10

liuhuangbo (审核中...)

前往app查看评论内容

#贝达奎宁#

EUR RESPIR J：贝达奎宁治疗耐多药结核的长期有效性和安全性

2020-04-01

liuhuangbo (审核中...)

前往app查看评论内容

#贝达奎宁#

LANCET RESP MED：贝达奎宁显著降低耐药结核病患者的死亡率

2020-04-01

科室
- - 订阅+
  - 更多科室
工具
服务